JNJ - Is Emergent BioSolutions Stock a Buy?
The stock of Emergent BioSolutions (NYSE: EBS) has been on fire of late. Year to date, shares are up by 56.6%, while the S&P 500 is down by 9.3%. What's behind Emergent's strong performance amid a highly volatile stock market and challenging economic conditions? The company has been involved in the race to develop a vaccine for COVID-19.
Specifically, Emergent signed several contract development and manufacturing agreements with other companies that are currently developing vaccines for the coronavirus. Emergent does have more than just its COVID-19 deals going on, though. With that in mind, let's dig into the company's business and find out whether Emergent can continue outperforming the market.